Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases

Current Oncology Reports

Volumn 9, Issue 3, 2007, Pages 193-201

  Pawlik, Timothy M ^b   Choti, Michael A ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; DNA; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN BAX; PROTEIN P53; TELOMERASE REVERSE TRANSCRIPTASE; THYMIDINE; THYMIDYLATE SYNTHASE;

ANTIGEN DETECTION; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA MICROARRAY; DNA SEQUENCE; DRUG RESPONSE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LIVER RESECTION; MOLECULAR BIOLOGY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SEQUENCE ANALYSIS; UNIVARIATE ANALYSIS;

COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34248379100     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-007-0021-4     Document Type: Review

References (111)

1. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
2. Steele G Jr, Ravikumar TS: Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 1989, 210:127-138.
3. Jaffe BM, Donegan WL, Watson F, Spratt JS Jr: Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet 1968, 127:1-11.
4. Bengmark S, Hafstrom L: The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 1969, 23:198-202.
5. de Brauw LM, van de Velde CJ, Bouwhuis-Hoogerwerf ML, Zwaveling A: Diagnostic evaluation and survival analysis of colorectal cancer patients with liver metastases. J Surg Oncol 1987, 34:81-86.
6. Bengtsson G, Carlsson G, Hafstrom L, Jonsson PE: Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981, 141:586-589.
7. Goslin R, Steele G Jr, Zamcheck N, et al.: Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum 1982, 25:749-754.
8. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-analysis Project. J Clin Oncol 1992, 10:896-903.
9. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343:905-914.
10. de Gramont A, Bosset JF, Milan C, et al.: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997, 15:808-815.
11. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
12. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22:23-30.
13. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
14. Cunningham D, Pyrhonen S, James RD, et al.: Randomised trial of irinotecan plus supportive care versus supportive care alone after flnorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413-1418.
15. Rougier P, Van Cutsem E, Bajetta E, et al.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407-1412.
16. Rothenberg ML, Oza AM, Bigelow RH, et al.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003, 21:2059-2069.
17. Hurwitz H, Fehrenbacher L, Novomy W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
18. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208.
19. Moertel CG, Gunderson LL, Mailliard JA, et al.: Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment Group. J Clin Oncol 1994, 12:21-27.
20. Fong Y, Fortner J, Sun RL, et al.: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230:309-321.
21. Vauthey JN, Pawlik TM, Abdalla EK, et al.: Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg 2004, 239:722-732.
22. Rosen CB, Nagorney DM, Taswell HF, et al.: Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 1992, 216:493-505.
23. Abdalla EK, Vauthey JN, Ellis LM, et al.: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004, 239:818-827.
24. Scheele J, Stangl R, Altendorf-Hofmann A: Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990, 77:1241-1246.
25. Choti MA, Sitzmann JV, Tiburi MF, et al.: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002, 235:759-766.
26. Hughes KS, Rosenstein RB, Songhorabodi S, et al.: Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors. Dis Colon Rectum 1988, 31:1-4.
27. Adson MA, van Heerden JA, Adson MH, et al.: Resection of hepatic metastases from colorectal cancer. Arch Surg 1984, 119:647-651.
28. Schlag P, Hohenberger P, Herfarth C: Resection of liver metastases in colorectal cancer - competitive analysis of treatment results in synchronous versus metachronous metastases. Eur J Surg Oncol 1990, 16:360-365.
29. Gayowski TJ, Iwatsuki S, Madariaga JR, et al.: Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 1994, 116:703-711.
30. Jenkins LT, Millikan KW, Bines SD, et al.: Hepatic resection for metastatic colorectal cancer. Am Surg 1997, 63:605-610.
31. Jamison RL, Donohue JH, Nagorney DM, et al.: Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997, 132:505-511.
32. Hughes KS, Simon R, Songhorabodi S, et al.: Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986, 100:278-284.
33. Scheele J, Stang R, Altendorf-Hofmann A, Paul M: Resection of colorectal liver metastases. World J Surg 1995, 19:59-71.
34. Fong Y, Cohen AM, Fortner JG, et al.: Liver resection for colorectal metastases. J Clin Oncol 1997, 15:938-946.
35. Nitti D, Belluco C, Montesco MC, et al.: Nuclear p53 protein expression in resected hepatic metastases from colorectal cancer: an independent prognostic factor of survival. Eur J Cancer 1998, 34:851-855.
36. Weber JC, Nakano H, Bachellier P, et al.: Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? Am J Surg 2001, 182:81-88.
37. de Jong KP, Lont HE, Bijma AM, et al.: The effect of partial hepatectomy on tumor growth in rats: in vivo and in vitro studies. Hepatology 1995, 22:1263-1272.
38. Gonen M, Hummer A, Zervoudakis A, et al.: Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol 2003, 21:406-412.
39. Smith DL, Soria JC, Morat L, et al.: Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann Surg Oncol 2004, 11:45-51.
40. Domont J, Pawlik TM, Boige V, et al.: Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis. J Clin Oncol 2005, 23:3086-3093.
41. Nordlinger B, Guiguet M, Vaillant JC, et al.: Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996, 77:1254-1262.
42. Mann CD, Metcalfe MS, Leopardi LN, Maddern GJ: The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg 2004, 139:1168-1172.
43. Wang JY, Chiang JM, Jeng LB, et al.: Resection of liver metastases from colorectal cancer: are there any truly significant clinical prognosticators? Dis Colon Rectum 1996, 39:847-851.
44. Aldrighetti L, Castoldi R, Di Palo S, et al.: [Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases.] Chir Ital 2005, 57:555-570.
45. Mala T, Bohler G, Mathisen O, et al.: Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World J Surg 2002, 26:1348-1353.
46. Fortner JG, Silva JS, Golbey RB, et al.: Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg 1984, 199:306-316.
47. Doci R, Gennari L, Bignami P, et al.: One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg 1991, 78:797-801.
48. Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP: Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 1991, 110:13-29.
49. Ekberg H, Tranberg KG, Andersson R, et al.: Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986, 73:727-731.
50. Weber SM, Jarnagin WR, DeMatteo RP, et al.: Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol 2000, 7:643-650.
51. Cady B, Stone MD, McDermott WV Jr, et al.: Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases. Arch Surg 1992, 127:561-569.
52. Kokudo N, Imamura H, Sugawara Y, et al.: Surgery for multiple hepatic colorectal metastases. J Hepatobiliary Pancreat Surg 2004, 11:84-91.
53. Bolton JS, Fuhrman GM: Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg 2000, 231:743-751.
54. Adam R, Pascal G, Castaing D, et al.: Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004, 240:1052-1064.
55. Pawlik TM, Abdalla EK, Ellis LM, et al.: Debunking dogma: surgery for four or more colorectal liver metastases is justified. J Gastro Surg 2006, In press.
56. Nagakura S, Shirai Y, Yamato Y, et al.: Simultaneous detection of colorectal carcinoma liver and lung metastases does not warrant resection. J Am Coll Surg 2001, 193:153-160.
57. 0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004, 11:274-280.
58. Ferrero A, Polastri R, Muratore A, et al.: Extensive resections for colorectal liver metastases. J Hepatobiliary Pancreat Surg 2004, 11:92-96.
59. Elias D, Ouellet JF, Bellon N, et al.: Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg 2003, 90:567-574.
60. Inoue M, Kotake Y, Nakagawa K, et al.: Surgery for pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2000, 70:380-383.
61. McAfee MK, Allen MS, Trastek VF, et al.: Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992, 53:780-786.
62. Sakamoto T, Tsubota N, Iwanaga K, et al.: Pulmonary resection for metastases from colorectal cancer. Chest 2001, 119:1069-1072.
63. Mansel JK, Zinsmeister AR, Pairolero PC, Jett JR: Pulmonary resection of metastatic colorectal adenocarcinoma. A ten year experience. Chest 1986, 89:109-112.
64. Inoue M, Ohta M, Iucbi K, et al.: Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg 2004, 78:238-244.
65. Cady B, Stone MD: The role of surgical resection of liver metastases in colorectal carcinoma. Semin Oncol 1991, 18:399-406.
66. Belluco C, Guillem JG, Kemeny N, et al.: p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 1996, 14:2696-2701.
67. Costa A, Doci R, Mochen C, et al.: Cell proliferation-related markers in colorectal liver metastases: correlation with patient prognosis. J Clin Oncol 1997, 15:2008-2014.
68. Petrowsky H, Sturm I, Graubitz O, et al.: Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol 2001, 27:80-87.
69. Lind DS, Parker GA, Horsley JS 3rd, et al.: Formal hepatic resection of colorectal liver metastases. Ploidy and prognosis. Ann Surg 1992, 215:677-684.
70. Crowe PJ, Yang JL, Berney CR, et al.: Genetic markers of survival and liver recurrence after resection of liver metastases from colorectal cancer. World J Surg 2001, 25:996-1001.
71. Saw RP, Koorey D, Painter D, et al.: p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer. Br J Surg 2002, 89:1409-1415.
72. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991, 253:49-53.
73. Kastan MB, Onyekwere O, Sidransky D, et al.: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991, 51:6304-6311.
74. Sturm I, Kohne CH, Wolff G, et al.: Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999, 17:1364-1374.
75. Hasegawa H, Ueda M, Furukawa K, et al.: p53 gene mutations in early colorectal carcinoma. De novo vs. adenoma-carcinoma sequence. Int J Cancer 1995, 64:47-51.
76. Wang A, Yoshimi N, Ino N, et al.: WAF1 expression and p53 mutations in human colorectal cancers. J Cancer Res Clin Oncol 1997, 123:118-123.
77. Pricolo VE, Finkelstein SD, Hansen K, et al.: Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma. Arch Surg 1997, 132:371-375.
78. Kastrinakis WV, Ramchurren N, Rieger KM, et al.: Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 1995, 11:647-652.
79. Ofner D, Riehemann K, Maier H, et al.: Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer 1995, 72:981-985.
80. Johnston PG, Fisher ER, Rockette HE, et al.: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994, 12:2640-2647.
81. Lenz HJ, Danenberg KD, Leichman CG, et al.: p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 1998, 4:1227-1234.
82. Allegra C: Thymidylate synthase levels: prognostic, predictive, or both? J Clin Oncol 2002, 20:1711-1713.
83. Allegra CJ, Parr AL, Wold LE, et al.: Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002, 20:1735-1743.
84. Aschele C, Debernardis D, Casazza S, et al.: Immunohistochemical quantitation of thymidylate syntbase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999, 17:1760-1770.
85. Davies MM, Johnston PG, Kaur S, Allen-Mersh TG: Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Clin Cancer Res 1999, 5:325-328.
86. Link KH, Kornmann M, Butzer U, et al.: Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy. Cancer 2000, 89:288-296.
87. Moyzis RK, Buckingham JM, Cram LS, et al.: A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A 1988, 85:6622-6626.
88. Blackburn EH: Structure and function of telomeres. Nature 1991, 350:569-573.
89. Greider CW: Telomeres. Curr Opin Cell Biol 1991, 3:444-451.
90. Yan P, Benhattar J, Seelentag W, et al.: Immunohistochemical localization of hTERT protein in human tissues. Histochem Cell Biol 2004, 121:391-397.
91. Shore D: Telomerase and telomere-binding proteins: controlling the endgame. Trends Biochem Sci 1997, 22:233-235.
92. Vaziri H, Dragowska W, Allsopp RC, et al.: Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci U S A 1994, 91:9857-9860.
93. Lindsey J, McGill NI, Lindsey LA, et al.: In vivo loss of telomeric repeats with age in humans. Mutat Res 1991, 256:45-48.
94. Shay JW, Wright WE: Telomerase activity in human cancer. Curr Opin Oncol 1996, 8:66-71.
95. Yang Y, Chen Y, Zhang C, et al.: Nucleolar localization of hTERT protein is associated with telomerase function. Exp Cell Res 2002, 277:201-209.
96. Etheridge KT, Banik SS, Armbruster BN, et al.: The nucleolar localization domain of the catalytic subunit of human telomerase. J Biol Chem 2002, 277:24764-24770.
97. Lantuejoul S, Soria JC, Moro-Sibilot D, et al.: Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer 2004, 90:1222-1229.
98. Kim NW, Piatyszek MA, Prowse KR, et al.: Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
99. Yoo J, Park SY, Kang SJ, et al.: Expression of telomerase activity, human telomerase RNA, and telomerase reverse transcriptase in gastric adenocarcinomas. Mod Pathol 2003, 16:700-707.
100. Kanaya T, Kyo S, Takakura M, et al.: hTERT is a critical determinant of telomerase activity in renal-cell carcinoma. Int J Cancer 1998, 78:539-543.
101. Liu YC, Chen CJ, Wu HS, et al.: Telomerase and c-myc expression in hepatocellular carcinomas. Eur J Surg Oncol 2004, 30:384-390.
102. Niiyama H, Mizumoto K, Sato N, et al.: Quantitative analysis of hTERT mRNA expression in colorectal cancer. Am J Gastroenterol 2001, 96:1895-1900.
103. Chadeneau C, Hay K, Hirte HW, et al.: Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res 1995, 55:2533-2536.
104. Stremmel C, Wein A, Hohenberger W, Reingruber B: DNA microarrays: a new diagnostic tool and its implications in colorectal cancer. Int J Colorectal Dis 2002, 17:131-136.
105. Mehta KR, Nakao K, Zuraek MB, et al.: Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clin Cancer Res 2005, 11:1791-1797.
106. Tanaka K, Adam R, Shimada H, et al.: Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003, 90:963-969.
107. Weber JC, Navarra G, Jiao LR, et al.: New technique for liver resection using heat coagulative necrosis. Ann Surg 2002, 236:560-563.
108. Parikh AA, Gentner B, Wu TT, et al.: Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 2003, 7:1082-1088.
109. Allen PJ, Kemeny N, Jarnagin W, et al.: Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003, 7:109-117.
110. Nordlinger B, Quilichini MA, Parc R, et al.: Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrences in 80 patients. Ann Surg 1987, 205:256-263.
111. Fong Y, Saldinger PF, Akhurst T, et al.: Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999, 178:282-287.